JP2022547733A5 - - Google Patents

Info

Publication number
JP2022547733A5
JP2022547733A5 JP2022517173A JP2022517173A JP2022547733A5 JP 2022547733 A5 JP2022547733 A5 JP 2022547733A5 JP 2022517173 A JP2022517173 A JP 2022517173A JP 2022517173 A JP2022517173 A JP 2022517173A JP 2022547733 A5 JP2022547733 A5 JP 2022547733A5
Authority
JP
Japan
Prior art keywords
seq
antibody
composition according
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022517173A
Other languages
English (en)
Japanese (ja)
Other versions
JP7717687B2 (ja
JP2022547733A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050974 external-priority patent/WO2021055409A1/en
Publication of JP2022547733A publication Critical patent/JP2022547733A/ja
Publication of JP2022547733A5 publication Critical patent/JP2022547733A5/ja
Priority to JP2025123268A priority Critical patent/JP2025165991A/ja
Application granted granted Critical
Publication of JP7717687B2 publication Critical patent/JP7717687B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022517173A 2019-09-16 2020-09-16 腎疾患における抗幹細胞因子抗体及びその使用方法 Active JP7717687B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025123268A JP2025165991A (ja) 2019-09-16 2025-07-23 腎疾患における抗幹細胞因子抗体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900927P 2019-09-16 2019-09-16
US62/900,927 2019-09-16
PCT/US2020/050974 WO2021055409A1 (en) 2019-09-16 2020-09-16 Anti-stem cell factor antibodies and methods of use thereof in renal disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025123268A Division JP2025165991A (ja) 2019-09-16 2025-07-23 腎疾患における抗幹細胞因子抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2022547733A JP2022547733A (ja) 2022-11-15
JP2022547733A5 true JP2022547733A5 (https=) 2023-09-22
JP7717687B2 JP7717687B2 (ja) 2025-08-04

Family

ID=74868426

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022517136A Active JP7698635B2 (ja) 2019-09-16 2020-09-16 抗幹細胞因子抗体及びその使用方法
JP2022517173A Active JP7717687B2 (ja) 2019-09-16 2020-09-16 腎疾患における抗幹細胞因子抗体及びその使用方法
JP2025099435A Pending JP2025125563A (ja) 2019-09-16 2025-06-13 抗幹細胞因子抗体及びその使用方法
JP2025123268A Pending JP2025165991A (ja) 2019-09-16 2025-07-23 腎疾患における抗幹細胞因子抗体及びその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022517136A Active JP7698635B2 (ja) 2019-09-16 2020-09-16 抗幹細胞因子抗体及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025099435A Pending JP2025125563A (ja) 2019-09-16 2025-06-13 抗幹細胞因子抗体及びその使用方法
JP2025123268A Pending JP2025165991A (ja) 2019-09-16 2025-07-23 腎疾患における抗幹細胞因子抗体及びその使用方法

Country Status (28)

Country Link
US (5) US20220324957A1 (https=)
EP (3) EP4031569B1 (https=)
JP (4) JP7698635B2 (https=)
KR (1) KR20220079561A (https=)
CN (2) CN118561997A (https=)
AR (1) AR119979A1 (https=)
AU (2) AU2020348295A1 (https=)
BR (1) BR112022004776A2 (https=)
CA (2) CA3154649A1 (https=)
CL (1) CL2022000633A1 (https=)
CO (1) CO2022003661A2 (https=)
DK (1) DK4031569T3 (https=)
DO (1) DOP2022000058A (https=)
EC (1) ECSP22022676A (https=)
ES (1) ES3053942T3 (https=)
FI (1) FI4031569T3 (https=)
IL (1) IL291385A (https=)
MX (1) MX2022003159A (https=)
PE (1) PE20230090A1 (https=)
PH (1) PH12022550647A1 (https=)
PL (1) PL4031569T3 (https=)
PT (1) PT4031569T (https=)
SA (1) SA522431966B1 (https=)
TW (2) TWI875812B (https=)
UA (1) UA129546C2 (https=)
UY (1) UY38883A (https=)
WO (2) WO2021055408A1 (https=)
ZA (1) ZA202203272B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
AU2020348295A1 (en) * 2019-09-16 2022-04-07 Insmed Incorporated Anti-stem cell factor antibodies and methods of use thereof
KR20250167153A (ko) * 2023-03-03 2025-11-28 셀덱스 쎄라퓨틱스, 인크. 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
WO2026079764A1 (ko) * 2024-10-10 2026-04-16 아주대학교산학협력단 마우스 scf를 중화하는 항체 및 이의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2657113B2 (ja) * 1989-10-16 1997-09-24 アムジエン・インコーポレーテツド 幹細胞因子
US7144731B2 (en) * 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5911988A (en) 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
JP3583214B2 (ja) 1995-12-01 2004-11-04 株式会社ニチレイ ヒトscfに対するモノクローナル抗体
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
PL1691837T3 (pl) 2003-12-10 2012-11-30 Squibb & Sons Llc IP-10 przeciwciała i ich zastosowanie
US7611707B2 (en) 2004-04-29 2009-11-03 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods thereof
WO2006002064A2 (en) 2004-06-14 2006-01-05 Aerovance, Inc. Antibody inhibiting stem cell factor activity and use for treatment of asthma
US20080248050A1 (en) 2006-06-30 2008-10-09 Uchicago Argonne, Llc Meta-specific vaccine, method for treating patients immunized with meta-specific vaccine
US20110189093A1 (en) 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
AU2012205718B2 (en) 2011-01-10 2017-07-06 The Regents Of The University Of Michigan Stem cell factor inhibitor
US20150018408A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
KR101384360B1 (ko) 2012-05-04 2014-04-14 아주대학교산학협력단 Scf 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
US10927153B1 (en) 2015-05-20 2021-02-23 University Of South Florida Synthetic plasmodium antigens, compositions, and uses thereof
KR102438650B1 (ko) * 2015-08-19 2022-08-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
KR20170022409A (ko) 2015-08-20 2017-03-02 주식회사 와이바이오로직스 Scf 특이적 항체
US11091559B2 (en) * 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
CA3009488A1 (en) 2015-12-22 2017-06-29 Abbvie Stemcentrx Llc Novel anti-upk1b antibodies and methods of use
PL3523421T3 (pl) 2016-10-05 2025-06-09 Cellresearch Corporation Pte. Ltd. Sposób izolowania mezenchymalnych komórek macierzystych z błony owodniowej pępowiny przy użyciu podłoża do hodowli komórkowej
WO2019066093A1 (ko) 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
WO2019088658A1 (ko) 2017-10-31 2019-05-09 주식회사 컴워스파마 Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
KR102131898B1 (ko) 2017-10-31 2020-07-08 주식회사 노벨티노빌리티 Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
CA3117098A1 (en) 2018-10-19 2020-04-23 The General Hospital Corporation Compositions and methods for treatment of liver disease
AU2020348295A1 (en) 2019-09-16 2022-04-07 Insmed Incorporated Anti-stem cell factor antibodies and methods of use thereof
US20240182556A1 (en) 2021-03-17 2024-06-06 Opsidio, LLC Stem cell factor antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2022547733A5 (https=)
JP2025016349A5 (https=)
JP2023134618A5 (https=)
JP2020055849A5 (https=)
JP2019522961A5 (https=)
JP2018516853A5 (https=)
JP2022545196A5 (https=)
JP2023551027A5 (https=)
JP2023071956A5 (https=)
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2016529882A5 (https=)
JP2012504955A5 (https=)
RU2012147286A (ru) Гуманизированные антитела к фактору d и их применения
JP2018508188A5 (https=)
RU2014151788A (ru) Молекула, специфически связывающаяся с rsv
JP2024059791A5 (https=)
JP2012500020A5 (https=)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
JP2016512551A5 (https=)
JP2010538608A5 (https=)
JP2009225799A5 (https=)
RU2010150105A (ru) Гуманизированные антитела против альфа-интерферона человека
JP2022538232A5 (https=)
JP2016513682A5 (https=)
WO2021012195A1 (zh) 可结合sftsv的纳米抗体及其应用